BiologicalDrug
Pelareorep clinical trials
Also written Reolysin and PO BB0209.
- studies test it
- 31
- open now
- 1
- in phase 3
- 1
- first study started
- 2006
Keep track of what changes. Save the pelareorep studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 5 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 17
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 17
Oncolytics Biotech (13) · National Cancer Institute (NCI) (7) · Canadian Cancer Trials Group (4) · University of Southern California (2) · Mridula George, MD (1) · Adlai Nortye Biopharma Co., Ltd. (1) · Emory University (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Paclitaxel (4) · Carboplatin (4) · Dexamethasone (2) · Bevacizumab (2) · Docetaxel (2) · Gemcitabine (2) · Retifanlimab (1) · Avelumab (1)
Studies
Open first, then newest update. How each study uses pelareorep is read from its arms, and is right about nine times in ten.
Testing it · 31
- FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerRecruitingPhase 2Oncolytics BiotechNCT07446322Written as Pelareorep
- Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialActive, not recruitingPhase 1/2University of Southern CaliforniaNCT05514990Written as Pelareorep
- INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyActive, not recruitingPhase 2Mridula George, MDNCT04445844Written as Pelareorep
- A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyActive, not recruitingPhase 2Oncolytics BiotechNCT04215146Written as Pelareorep
- Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1National Cancer Institute (NCI)NCT02101944Written as Pelareorep
- Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast CancerCompletedPhase 1Adlai Nortye Biopharma Co., Ltd.NCT05519059Written as Pelareorep
- Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaCompletedPhase 1Emory UniversityNCT03605719Written as Pelareorep
- Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal CancerCompletedPhase 2Canadian Cancer Trials GroupNCT01622543Written as Folfox plus Bevacizumab and reolysin
- Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1University of Southern CaliforniaNCT02514382Written as Wild-type Reovirus
- A Study of Reolysin For Patients With Advanced/Metastatic Breast CancerCompletedPhase 2Canadian Cancer Trials GroupNCT01656538Written as Reolysin
- Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate CancerCompletedPhase 2Canadian Cancer Trials GroupNCT01619813Written as Docetaxel, Reolysin and Prednisone
- Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage TherapyCompletedPhase 2Canadian Cancer Trials GroupNCT01708993Written as Pemetrexed and Reolysin (and safety run-in)
- Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain TumorsCompletedPhase 1Mayo ClinicNCT02444546Written as Wild-type Reovirus
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 2National Cancer Institute (NCI)NCT01199263Written as Pelareorep
- Viral Immunotherapy in Relapsed/Refractory Multiple MyelomaStatus unknownPhase 1University of LeedsNCT03015922Written as REOLYSIN
- Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal CancerCompletedPhase 1Oncolytics BiotechNCT01274624Written as REOLYSIN®
- Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedPhase 1Oncolytics BiotechNCT02620423Written as REOLYSIN®
- Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedPhase 2National Cancer Institute (NCI)NCT01280058Written as Wild-type Reovirus
- Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the BladderWithdrawnPhase 1Oncolytics BiotechNCT02723838Written as REOLYSIN®
- Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum ChemotherapyCompletedPhase 1National Cancer Institute (NCI)NCT00602277Written as Wild-type Reovirus
See all 31 studies that test pelareorep →
Given in every arm · 4 — pelareorep is usual care beside what is tested
- A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabActive, not recruitingPhase 1/2Oncolytics BiotechNCT07280377Written as Pelareorep
- Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic CancerTerminatedPhase 2Northwestern UniversityNCT03723915Written as Wild-type Reovirus
- A Window-of-opportunity Study of Pelareorep in Early Breast CancerTerminatedEarly Phase 1Oncolytics BiotechNCT04102618Written as Pelareorep
- REO13 Melanoma With of Without GM-CSFWithdrawnPhase 1/2University of LeedsNCT03282188Written as Reolysin
Codes
What other systems call pelareorep · ClinicalTrials.gg INT017881
- UNII (FDA) S9J80L3D1UPELAREOREPOne source FDA
- NCI Thesaurus C60774PelareorepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S9J80L3D1U | PELAREOREP | One source FDA |
| NCI Thesaurus | C60774 | Pelareorep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.